The relevance of HLA-Cw6 in psoriasis pathogenesis has also been confirmed by pharmacogenomic studies showing that its presence in patients associates with better response to the anti-IL-12/IL-23p40 ustekinumab [17,18] or anti-IL-17A secukinumab drugs [19]. The gene discussed is IL17A; the disease is psoriasis.